2018–2020 DRC North Kivu Ebola Outbreak

The second-largest Ebola outbreak in history — 3,481 cases and 2,299 deaths in an active conflict zone, and the trial that led to Ervebo's approval.

Outbreak Summary

Conflict as the Defining Challenge

The North Kivu outbreak was the most operationally challenging Ebola response ever mounted. The region is home to dozens of armed groups, and Ebola response teams — perceived by some communities as allied with government forces — were attacked more than 300 times. Six health workers were killed. Ebola Treatment Unit facilities were attacked and burned. Community resistance, fueled by distrust built over decades of conflict and humanitarian presence, led families to hide sick relatives and conduct secret burials. The WHO PHEIC was declared on July 17, 2019 — nearly a year into the outbreak — partly triggered when a case reached Goma, a city of 2 million near the Rwandan border.

Vaccine and Treatment Breakthroughs

The North Kivu outbreak served as the deployment setting for a landmark randomized controlled trial of four Ebola treatments (Inmazeb/REGN-EB3, mAb114, ZMapp, remdesivir). The trial found Inmazeb (REGN-EB3, a monoclonal antibody cocktail) and mAb114 substantially reduced mortality (survival rates of 90%+ when treated early, versus ~25% with ZMapp). These results led to FDA approval of Inmazeb and Ebanga (mAb114). Concurrently, ring vaccination with Ervebo (rVSV-ZEBOV) reached approximately 300,000 people and was credited with substantially limiting epidemic size given the challenging operating environment.

Sources: WHO DRC North Kivu Ebola situation reports; NEJM (Mulangu et al. PALM trial treatments); Lancet PHEIC DRC Ebola analysis; MSF North Kivu response reports.

Related: Ebola overview · 2014 Ebola epidemic · DRC Ebola

Timeline: August 2018 to June 2020

• Aug 1, 2018: DRC Ministry of Health declares outbreak in Mangina, North Kivu province
• Aug 2018: First Ebola Treatment Units established; ring vaccination with Ervebo begins immediately
• Sep 2018: Outbreak spreads to Beni — a densely populated urban center with active armed groups
• Nov 2018: First attack on an Ebola Treatment Unit; response teams withdraw temporarily
• Mar 2019: Butembo (pop. ~1 million) becomes a major epicenter; health workers attacked repeatedly
• Apr 2019: WHO director calls epidemic "deeply concerning" but stops short of PHEIC
• Jun 2019: First cases in Uganda (imported); Goma, a crossroads city of 2 million, records first case
• Jul 17, 2019: WHO declares PHEIC — 11 months after outbreak start, triggered by the Goma case
• Aug 2019: PALM trial results confirm Inmazeb and mAb114 superiority over ZMapp and remdesivir
• Feb 2020: New sub-epicenter in South Kivu; outbreak shows signs of waning
• Jun 25, 2020: DRC declares end of outbreak — as COVID-19 pandemic peaks globally

The PHEIC Debate: Eleven Months of Hesitation

The North Kivu outbreak generated significant controversy around the PHEIC declaration process. WHO convened its Emergency Committee four times before declaring a PHEIC — despite escalating cases and conflict zone challenges that many experts argued warranted earlier action. Critics argued that PHEIC hesitancy stemmed partly from fears that declaration would trigger travel and trade restrictions that would further isolate an already fragile region. The Goma case — a single imported case in a city of 2 million near the Rwandan border — finally triggered the declaration on July 17, 2019, nearly a year into the outbreak. The episode renewed debate about whether the PHEIC threshold is appropriately calibrated, or whether economic and political considerations unduly influence the process. The WHO's own review later acknowledged the delayed declaration as a subject warranting examination.

Legacy: Treatments That Redefined Ebola Outcomes

The North Kivu outbreak permanently changed Ebola treatment. Before 2019, Ebola had no approved specific therapy; death rates in previous outbreaks ran at 50–90%. The PALM trial — a randomized controlled trial conducted amid active conflict — demonstrated that both Inmazeb (atoltivimab, maftivimab, odesivimab) and Ebanga (ansuvimab/mAb114) could dramatically reduce mortality: patients treated early had survival rates exceeding 90%, compared to approximately 25% with ZMapp. FDA approved Inmazeb in October 2020 and Ebanga in December 2020 — the first approved Ebola treatments in history. Ervebo ring vaccination, reaching approximately 300,000 contacts, added a prophylactic layer. These breakthroughs mean that future Ebola outbreaks, if detected early and treated with available medicines, need not carry the catastrophic mortality of prior epidemics.